Company News: Medivation, Hacker Group and HealthHG

Share this article:
San Francisco-based biotech Medivation said it will cut 23 positions – a fifth of its staff – as part of a cost-cutting exercise in the wake of the failure of Alzheimer's drug candidate dimebon, which the firm was partnering with Pfizer on. Medivation will continue to work on Alzheimer's and Huntington disease applications for dimebon and on its MDV3100 for prostate cancer.

Hacker Group, a Seattle-based digital and direct marketing shop, announced that it is launching a health insurance marketing practice, dubbed HealthHG. The practice will be led by VP account services Jill Kaufman and chief strategist Tom Reid. Clients include Highmark Blue Shield, EmblemHealth and Blue Cross Blue Shield of Alabama.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.